Member Info for Laura2022

Hello Keith

Same could be said of all of AIM over last 2yrs with many macro headwinds however PYC is genuinely starting to look likely to turn a profit in 2025 if current contract wins and conversion of £1.7mln pipeline continues

In a A.I/drug development sector which is thriving

I've listened properly and fully

Compared to Suzy , Kevin and countless other BODs he speaks robustly and to point with fluency and ease

I particularly liked his reply on 37mins regarding the VAL201/EUDA question ..he said there would be updates in "coming weeks" and is "currently with lawyers"

This of course could mena many things

And his salary is?.??

Good to have a new face

I will be buying more tomorrow..I couldn't buy at 0.65p

Hi Jim

I hadn't bought...It was because my app was saying 2mln+ volume and 15+ trades yet LSE here wasn't showing anything

When i went to buy more it was negotiating order

Hello Dr Jim

It looks like lots of buying has not been reported on this site

Welcome to the PYC

Physiomics plc

1,684 followers

22h

🛫 Barcelona-bound! 🎉 The Physiomics plc team is heading to the EORTC-NCI-AACR Symposium tomorrow, and we’re looking forward to joining the global conversation on oncology innovation.

If you’ll be there, be sure to catch Léa Sta, PhD’s poster presentation on Thursday 24th October (Poster Number 240), featuring results from our PARTNER study – our exciting step towards a personalised oncology dosing tool. 💡

We’re really looking forward to meeting fellow R&D leaders and discussing how Model-Informed Drug Development (MIDD) can improve drug development decisions and optimise dosing strategies.

They are presenting the info to a new audience

The poster on this forum BD

The conference only just started today

Ralph

Give them time !!

800,000

800k+ nit showing

https://www.londonstockexchange.com/stock/PYC/physiomics-plc/company-page

Volume now 2.4mln but LSE not showing trades agsin .?

In fact £1000

Currently it's NT for £1500

Maybe concentrate on SCE

More than £3/4k

I'm grateful i could buy a month or so ago at 9p and 10p

KingHomerJ

Posted in: PYC

Posts: 1,613

Price: 0.70

No Opinion

RE: 0.811 Oct 2024 15:18

Sorry also missed out it is also in trial for G-CSF which has a $10Billion Annual Market.....

KingHomerJ

Posted in: PYC

Posts: 1,613

Price: 0.70

No Opinion

RE: 0.811 Oct 2024 14:05

PYC are in the best position they ever have been.

The New CEO Pete is very driven and has an exceptional background.

The revenue is the highest it ever has been going into a new financial year with the biggest pipeline with contracted revenues up until 2027...This alone warrants a MC in the multiples of current

The new biostats (new revenue stream) can itself produce far greater revenues that the current VT tech. (see recent presentation) Again multiples on the multiples

The Dosing tool which effectively is in two trials with NHS- Beyond Blood & Dosemerx in the US has the potential to add tens of Millions in revenue with the sheer saving it would save on the Docetaxel (Taxotere) Chemo

Docetaxel is a blockbuster cancer drug with peak global sales of £3.1 Billion and rising

Facts , as Mozak says are PYC are £1.4mln yet

Record revenues won 2023/24

Record revenues booked 2024 already for H2

Cash of £600k or so after recent fund raise

Potential for up to £6mln from VAL201 sub license ( see Feb 2021)

Personalised medicine software platforms are worth $blns in savings and PYC are at final stages of their software dosing app being at revenue generation stage largely with USA partner DoseMeRx

Directors have lowest wages on AIM..eg CEO at £70k is a fraction of other unscrupulous CeoS on AIM

A very good recent webinar ( see Trench123 notes)

Personalised dosing app nearing commercialisation (see King Homer posts)